Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II study of rintatolimod to enhance the immune mediated effects of CPIs in patients with advanced solid tumors

Trial Profile

Phase I/II study of rintatolimod to enhance the immune mediated effects of CPIs in patients with advanced solid tumors

Planning
Phase of Trial: Phase I/II

Latest Information Update: 07 Jun 2018

At a glance

  • Drugs Rintatolimod (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2018 New trial record
    • 31 May 2018 According to a Hemispherx Biopharma media release, This study will be led by Pawel Kalinski, MD, PhD, who currently serves as the Vice Chair for Translational Research and Professor of Oncology in the Department of Medicine and as the Co-Leader for the Tumor Immunology & Immunotherapy Program at Roswell Park.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top